Monday 12 October 2026
Export all AMGN data to Excel Powerpack
Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
414.87
7.43
+1.82%
Follow AMGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
81.71% | 106.10% | 101.32% | 91.47% | |
Piotroski F-Score |
7 | 7 | 8 | 8 | |
| 7.74% | 8.45% | 8.58% | 9.53% | ||
ROIC |
9.90% | 10.48% | 12.12% | 12.98% | |
Return on Tangible Assets |
52.61% | 67.16% | 52.93% | 48.56% | |
Average Days of Receivables |
86.15 | 95.05 | 89.61 | 97.99 | |
Free Cash Flow per Share |
21.45 | 15.06 | 15.92 | 18.84 | |
Free Cash Flow |
11,539.00 | 8,100.00 | 8,597.00 | 10,175.00 | |
Capital Expenditures |
(1,587.00) | (1,858.00) | (2,159.00) | (2,303.00) | |
| Other line items | |||||
Cash ROIC |
15.67% | 11.19% | 10.94% | 12.26% | |
Accounts Receivable Turnover |
4.55 | 4.50 | 4.31 | 4.03 | |
Accounts Payable Turnover |
4.88 | 5.63 | 4.42 | 3.95 | |
Inventory Turnover |
1.78 | 1.82 | 1.83 | 1.81 | |
Average Days of Payables |
85.10 | 71.77 | 90.69 | 90.05 | |
Days of Inventory on Hand |
190.28 | 188.76 | 191.14 | 195.50 | |
Tax Rate |
(0.15) | (0.14) | (0.14) | (0.15) | |
Research and Development Expense of Revenue |
19.05% | 19.79% | 20.16% | 20.03% | |
Selling, General and Administrative Expense of Revenue |
19.39% | 19.18% | 18.71% | 18.42% | |
Share Based Compensation of Revenue |
1.40% | 1.34% | 1.30% | 1.29% | |
Interest Coverage |
3.04 | 3.30 | 3.93 | 4.28 | |
Operating CF/Net income |
1.87 | 1.29 | 1.38 | 1.43 | |
Depreciation/Fixed assets |
0.92 | 0.80 | 0.64 | 0.59 | |
Capex/Depreciation |
(0.24) | (0.29) | (0.41) | (0.45) | |
Revenue per Share |
66.86 | 68.31 | 68.93 | 70.55 | |
Operating CF per Share |
24.40 | 18.51 | 19.92 | 23.11 | |
Capex per Share |
(2.95) | (3.45) | (4.00) | (4.26) | |
Capex to Sales |
0.04 | 0.05 | 0.06 | 0.06 |
Columns are period end dates